Browse drugs

…erapy –specifically those including pembrolizumab, dostarlimab, durvalumab, durvalumab plus olaparib, and atezolizumab–, in the treatment …

…receiving durvalumab, 25% receiving cemiplimab, 66.7% receiving avelumab, and 60% receiving the ipilimumab and nivolumab. A 61.5% of irA…

…The phase III ATOMIC trial recently showed that adding atezolizumab to standard adjuvant chemotherapy improved disease-free surviva…

…nd molecular determinants of pseudo-stability/progression after atezolizumab with and without bevacizumab across several histologies.Methods…

…nicalTrials.gov between 2014 and 2024 evaluating approved ICIs (nivolumab, pembrolizumab, atezolizumab, durvalumab, avelumab, ipilimumab,…

…8.9% were male and 51.1% were female. The most common ICIs were Pembrolizumab (16276, 45.38%), Nivolumab (10548, 29.41%), Ipilimumab (3120, 8…

…114 male and 50 female (unspecified 17). The ICIs involved were nivolumab (n=68), pembrolizumab (n=51), ipilimumab (n=35), atezolizumab (…

…cancer immunotherapy clinical trials (OAK and POPLAR, comparing atezolizumab to docetaxel in non-small cell lung cancer) as well as a separa…

…17;389(10066):255–265.Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Eng…

… in combination-treated tumor tissues was increased compared to Atezolizumab treatment alone.Conclusions Thus, shutting down EpCAM signaling…

… van Laarhoven HWM. Neoadjuvant chemoradiotherapy combined with atezolizumab for resectable esophageal adenocarcinoma: a single-arm phase II…

…with PD-L1 blockade. The EORTC-1508GCG phase II trial evaluated atezolizumab (anti-PD-L1), bevacizumab (anti-VEGF), and low-dose aspirin in …